Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery Published: 14 November 2024 Lisa Caproni, Ph.D. As gene therapy continues to evolve, nonviral DNA delivery is rapidly gaining traction…
Read More
ELENA STOYANOVA, PH.D. & TOM ADIE, PH.D. Touchlight is at the forefront of innovation in gene editing technology with our groundbreaking MegaBulb DNA (mbDNA). This novel, circular, single-stranded DNA template…
Read More
Touchlight is pioneering the next generation of DNA manufacturing with our transformative dbDNA™ technology. The enzymatic DNA manufacturing platform sets new industry standards for speed, purity, and scalability, overcoming the…
Read More
TOM MERRITT, PH.D. Traditional methods for the production of adeno-associated viral (AAV) vectors — crucial components in gene therapies — rely on plasmid DNA (pDNA), which can pose safety concerns…
Read More
Satish Muchakayala Antimicrobial resistance (AMR) is a global health threat and a complex problem that requires a united multisectoral approach. In the interest of patients and environmental safety, regulators around…
Read More
